The P-glycoprotein transport system and cardiovascular drugs

Journal of the American College of Cardiology

Volumn 61, Issue 25, 2013, Pages 2495-2502

  Wessler, Jeffrey D ^a   Grip, Laura T ^b   Mendell, Jeanne ^c   Giugliano, Robert P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

adverse drug event(s) drug drug interaction P glycoprotein pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; ATENOLOL; BISOPROLOL; CARDIOVASCULAR AGENT; CARVEDILOL; CLARITHROMYCIN; CLINDAMYCIN; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DIPYRIDAMOLE; DRONEDARONE; EDOXABAN; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; PLACEBO; PROPAFENONE; PROPRANOLOL; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; SOTALOL; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; P-GLYCOPROTEIN; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT;

EID: 84879232919     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.02.058     Document Type: Review

References (52)

1. K.M. Giacomini, S.M. Huang, and D.J. Tweedie Membrane transporters in drug development Nat Rev Drug Discov 9 2010 215 236
2. S.G. Aller, J. Yu, and A. Ward Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
3. J.H. Lin, and M. Yamazaki Clinical relevance of P-glycoprotein in drug therapy Drug Metab Rev 35 2003 417 454
4. S. Eyal, P. Hsiao, and J.D. Unadkat Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123 2009 80 104
5. B. Feng, J.B. Mills, and R.E. Davidson In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab Dispos 36 2008 268 275
6. L. Couture, J.A. Nash, and J. Turgeon The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart Pharmacol Rev 58 2006 244 258
7. F. Fenneteau, J. Turgeon, L. Couture, V. Michaud, J. Li, and F. Nekka Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination Theor Biol Med Model 6 2009 1 13
8. L.E. Shapiro, and N.H. Shear Drug interactions: proteins, pumps, and P-450s J Am Acad Dermatol 47 2002 467 484
9. I. Rodriguez, D.R. Abernethy, and R.L. Woosley P-glycoprotein in clinical cardiology Circulation 99 1999 472 474
10. T. Sakaeda, T. Nakamura, and K. Okumura Pharmacogenetics of drug transporters and its impact on the pharmacotherapy Curr Top Med Chem 4 2004 1385 1398
11. I.A. de Lannoy, and M. Silverman The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin Biochem Biophys Res Commun 189 1992 551 557
12. K.S. Fenner, M.D. Troutman, and S. Kempshall Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug Clin Pharmacol Ther 85 2009 173 181
13. B. Greiner, M. Eichelbaum, and P. Fritz The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J Clin Invest 104 1999 147 153
14. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, and D.M. Roden Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
15. K. Robinson, A. Johnston, S. Walker, J.P. Mulrow, W.J. McKenna, and D.W. Holt The digoxin-amiodarone interaction Cardiovasc Drugs Ther 3 1989 25 28
16. G. Santostasi, M. Fantin, I. Maragno, R.M. Gaion, O. Basadonna, and S. Dalla-Volta Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects J Cardiovasc Pharmacol 9 1987 385 390
17. L.A. Siddoway Amiodarone: guidelines for use and monitoring Am Fam Physician 68 2003 2189 2196
18. A. Vallakati, P.A. Chandra, M. Pednekar, R. Frankel, and J. Shani Dronedarone-induced digoxin toxicity: new drug, new interactions Am J Ther 2011 Apr 23 [E-pub ahead of print]; doi: 10.1097/MJT.0b013e31821106c9
19. S.J. Connolly, A.J. Camm, and J.L. Halperin Dronedarone in high-risk permanent atrial fibrillation N Engl J Med 365 2011 2268 2276
20. M.V. Calvo, A. Martin-Suarez, C. Martin Luengo, C. Avila, M. Cascon, and A. Dominguez-Gil Hurle Interaction between digoxin and propafenone Ther Drug Monit 11 1989 10 15
21. I. Bachmakov, U. Werner, B. Endress, D. Auge, and M.F. Fromm Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein Fundam Clin Pharmacol 20 2006 273 282
22. S. Schulman, U. Angeras, D. Bergqvist, B. Eriksson, M.R. Lassen, and W. Fisher Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients J Thromb Haemost 8 2010 202 204
23. M. Wadelius, K. Sorlin, and O. Wallerman Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors Pharmacogenomics J 4 2004 40 48
24. J.D. Douketis Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management Curr Pharm Des 16 2010 3436 3441
25. Pradaxa (dabigatran etexilate) [package insert] December 2012 Ridgefield CBIP Ingelheim, Germany
26. J.M. Walenga, and C. Adiguzel Drug and dietary interactions of the new and emerging oral anticoagulants Int J Clin Pract 64 2010 956 967
27. M. Legrand, J. Mateo, and A. Aribaud The use of dabigatran in elderly patients Arch Intern Med 171 2011 1285 1286
28. J. Stangier, H. Stahle, K. Rathgen, W. Roth, K. Reseski, and T. Kornicke Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin J Clin Pharmacol 52 2012 243 250
29. M.J. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, and S. Sandmann In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban J Pharmacol Exp Ther 338 2011 372 380
30. Xarelto (rivaroxaban) [package insert] 2012 Bayer HealthCare AG Leverkusen, Germany
31. J. Watson, G. Whiteside, and C. Perry Apixaban: first global approval Drugs 71 2011 2079 2089
32. Eliquis (apixaban) [package insert] 2013 Bristol-Myers Squibb New York
33. J. Mendell, H. Zahir, and G. Ridout Drug-drug interaction studies of cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving P-glycoprotein (P-gp), an efflux transporter, on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban, an oral factor Xa inhibitor (abstr) J Am Coll Cardiol 57 2011 E1510
34. C.T. Ruff, R.P. Giugliano, and E.M. Antman Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
35. M.E. Cavet, M. West, and N.L. Simmons Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells Br J Pharmacol 118 1996 1389 1396
36. M. Verschraagen, C.H. Koks, J.H. Schellens, and J.H. Beijnen P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol Res 40 1999 301 306
37. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano P-glycoprotein-mediated transcellular transport of MDR-reversing agents FEBS Lett 324 1993 99 102
38. K. Takara, T. Sakaeda, and Y. Tanigawara Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression Eur J Pharm Sci 16 2002 159 165
39. M. Kakumoto, T. Sakaeda, and K. Takara Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil Cancer Sci 94 2003 81 86
40. C.W. Holtzman, B.S. Wiggins, and S.A. Spinler Role of P-glycoprotein in statin drug interactions Pharmacotherapy 26 2006 1601 1607
41. R.A. Boyd, R.H. Stern, and B.H. Stewart Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion J Clin Pharmacol 40 2000 91 98
42. D. Taubert, N. von Beckerath, and G. Grimberg Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
43. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
44. K.H. Jung, K. Chu, and S.T. Lee Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel Clin Pharmacol Ther 90 2011 612 619
45. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
46. B.D. Damle, R. Sridhar, and P.B. Desai Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells Int J Cancer 56 1994 113 118
47. C. Verstuyft, S. Strabach, and H. El-Morabet Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition Clin Pharmacol Ther 73 2003 51 60
48. J.-S. Choi, and D.-H. Choi Pharmacokinetic drug interaction between carvedilol and ticlopidine in rats Biomol Ther 18 2010 343 349
49. R. Teng, S. Oliver, M.A. Hayes, and K. Butler Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects Drug Metab Dispos 38 2010 1514 1521
50. Marciniak TA. Ticagrelor for acute coronary syndromes, NDA 22-433. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM220192.pdf. Accessed December 13, 2011.
51. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf. Accessed November 2012.
52. J. Sahi, M.A. Milad, and X. Zheng Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor J Pharmacol Exp Ther 306 2003 1027 1034